참고문헌 참고문헌 참고문헌
1. Aarsland D, Ballard C, Larsen JP, McKeith I: A comparative study of psychiatric symptoms in dementia with Lewy bodies and Parkinson's disease with and without dementia. Int J Geriatr Psychiatry 16: 528-536, 2001
2. Aarsland D, Hutchinson M, Larsen JP: Cognitive, psychiatric and motor response to galantamine in Parkinson's disease with dementia. Int J Geriatr Psychiatry 18: 937-941, 2003
3. Aarsland D, Laake K, Larsen JP, Janvin C: Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study. J Neurol Neurosurg Psychiatry 72:
708-712, 2002
4. Ballard CG, Aarsland D, McKeith I, O'Brien J, Gray A, Cormack F, Burn D, Cassidy T, Starfeldt R, Larsen JP, Brown R, Tovee M: Fluctuations in attention: PD dementia vs DLB with parkinsonism. Neurology 59: 1714-1720, 2002
23
5. Beatty WW, Ryder KA, Gontkovsky ST, Scott JG, McSwan KL, Bharucha KJ: Analyzing the subcortical dementia syndrome of Parkinson's disease using the RBANS. Arch Clin Neuropsychol 18: 509-520, 2003
6. Bergman J, Lerner V: Successful use of donepezil for the treatment of psychotic symptoms in patients with Parkinson's disease. Clin Neuropharmacol 25: 107-110, 2002
7. Burn D, Emre M, McKeith I, De Deyn PP, Aarsland D, Hsu C, Lane R: Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease. Mov Disord 21: 1899-1907, 2006
8. Byrne EJ, Lennox GG, Godwin-Austen RB, Jefferson D, Lowe J, Mayer RJ, Landon M, Doherty FJ: Dementia associated with cortical Lewy bodies: proposed clinical diagnostic criteria. Dementia. Vol 2: Karger, 283-284, 1991
9. Emre M, Aarsland D, Albanese A, Byrne EJ, Deuschl G, De Deyn PP, Durif F, Kulisevsky J, van Laar T, Lees A, Poewe W, Robillard A, Rosa MM, Wolters E, Quarg P, Tekin S, Lane R: Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 351: 2509-2518, 2004
10. Emre M, Aarsland D, Brown R, Burn DJ, Duyckaerts C, Mizuno Y, Broe GA, Cummings J, Dickson DW, Gauthier S, Goldman J, Goetz C, Korczyn A, Lees A, Levy R,
24
Litvan I, McKeith I, Olanow W, Poewe W, Quinn N, Sampaio C, Tolosa E, Dubois B:
Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord 22: 1689-1707, 2007
11. Fabbrini G, Barbanti P, Aurilia C, Pauletti C, Lenzi GL, Meco G: Donepezil in the treatment of hallucinations and delusions in Parkinson's disease. Neurol Sci 23: 41-43, 2002
12. Goekoop R, Scheltens P, Barkhof F, Rombouts SA: Cholinergic challenge in Alzheimer patients and mild cognitive impairment differentially affects hippocampal activation--a pharmacological fMRI study. Brain 129: 141-157, 2006
13. Gron G, Brandenburg I, Wunderlich AP, Riepe MW: Inhibition of hippocampal function in mild cognitive impairment: targeting the cholinergic hypothesis. Neurobiol Aging 27:
78-87, 2006
14. Hilker R, Thomas AV, Klein JC, Weisenbach S, Kalbe E, Burghaus L, Jacobs AH, Herholz K, Heiss WD: Dementia in Parkinson disease: functional imaging of cholinergic and dopaminergic pathways. Neurology 65: 1716-1722, 2005
25
15. Hughes AJ, Daniel SE, Kilford L, Lees AJ: Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55: 181-184, 1992
16. Hughes TA, Ross HF, Musa S, Bhattacherjee S, Nathan RN, Mindham RH, Spokes EG:
A 10-year study of the incidence of and factors predicting dementia in Parkinson's disease.
Neurology 54: 1596-1602, 2000
17. Hutchinson M, Fazzini E: Cholinesterase inhibition in Parkinson's disease. J Neurol Neurosurg Psychiatry 61: 324-325, 1996
18. Lee PH, Kim JS, Shin DH, Yoon SN, Huh K: Cardiac 123I-MIBG scintigraphy in patients with drug induced parkinsonism. J Neurol Neurosurg Psychiatry 77: 372-374, 2006
19. Leroi I, Brandt J, Reich SG, Lyketsos CG, Grill S, Thompson R, Marsh L: Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson's disease. Int J Geriatr Psychiatry 19: 1-8, 2004
20. Mega MS, Cummings JL, O'Connor SM, Dinov ID, Reback E, Felix J, Masterman DL, Phelps ME, Small GW, Toga AW: Cognitive and metabolic responses to metrifonate therapy in Alzheimer disease. Neuropsychiatry Neuropsychol Behav Neurol 14: 63-68, 2001
26
21. Peppard RF, Martin WR, Carr GD, Grochowski E, Schulzer M, Guttman M, McGeer PL, Phillips AG, Tsui JK, Calne DB: Cerebral glucose metabolism in Parkinson's disease with and without dementia. Arch Neurol 49: 1262-1268, 1992
22. Peppard RF, Martin WR, Clark CM, Carr GD, McGeer PL, Calne DB: Cortical glucose metabolism in Parkinson's and Alzheimer's disease. J Neurosci Res 27: 561-568, 1990
23. Perry EK, Curtis M, Dick DJ, Candy JM, Atack JR, Bloxham CA, Blessed G, Fairbairn A, Tomlinson BE, Perry RH: Cholinergic correlates of cognitive impairment in Parkinson's disease: comparisons with Alzheimer's disease. J Neurol Neurosurg Psychiatry 48: 413-431, 1985
24. Piert M, Koeppe RA, Giordani B, Minoshima S, Kuhl DE: Determination of regional rate constants from dynamic FDG-PET studies in Parkinson's disease. J Nucl Med 37: 1115-1122, 1996
25. Pillon B, Deweer B, Agid Y, Dubois B: Explicit memory in Alzheimer's, Huntington's, and Parkinson's diseases. Arch Neurol 50: 374-379, 1993
27
26. Pillon B, Dubois B, Ploska A, Agid Y: Severity and specificity of cognitive impairment in Alzheimer's, Huntington's, and Parkinson's diseases and progressive supranuclear palsy.
Neurology 41: 634-643, 1991
27. Potkin SG, Anand R, Fleming K, Alva G, Keator D, Carreon D, Messina J, Wu JC, Hartman R, Fallon JH: Brain metabolic and clinical effects of rivastigmine in Alzheimer's disease. Int J Neuropsychopharmacol 4: 223-230, 2001
28. Quick MW, Lester RA: Desensitization of neuronal nicotinic receptors. J Neurobiol 53:
457-478, 2002
29. Rahkonen T, Eloniemi-Sulkava U, Rissanen S, Vatanen A, Viramo P, Sulkava R:
Dementia with Lewy bodies according to the consensus criteria in a general population aged 75 years or older. J Neurol Neurosurg Psychiatry 74: 720-724, 2003
30. Reading PJ, Luce AK, McKeith IG: Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial. Mov Disord 16: 1171-1174, 2001
31. Scatton B, Javoy-Agid F, Rouquier L, Dubois B, Agid Y: Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease. Brain Res 275: 321-328, 1983
28
32. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M: Alpha-synuclein in Lewy bodies. Nature 388: 839-840, 1997
33. Stefanova E, Wall A, Almkvist O, Nilsson A, Forsberg A, Langstrom B, Nordberg A:
Longitudinal PET evaluation of cerebral glucose metabolism in rivastigmine treated patients with mild Alzheimer's disease. J Neural Transm 113: 205-218, 2006
34. Stern Y, Richards M, Sano M, Mayeux R: Comparison of cognitive changes in patients with Alzheimer's and Parkinson's disease. Arch Neurol 50: 1040-1045, 1993
35. Stern Y, Tetrud JW, Martin WR, Kutner SJ, Langston JW: Cognitive change following MPTP exposure. Neurology 40: 261-264, 1990
36. Teipel SJ, Drzezga A, Bartenstein P, Moller HJ, Schwaiger M, Hampel H: Effects of donepezil on cortical metabolic response to activation during (18)FDG-PET in Alzheimer's disease: a double-blind cross-over trial. Psychopharmacology (Berl) 187: 86-94, 2006
37. Tune L, Tiseo PJ, Ieni J, Perdomo C, Pratt RD, Votaw JR, Jewart RD, Hoffman JM:
Donepezil HCl (E2020) maintains functional brain activity in patients with Alzheimer
29
disease: results of a 24-week, double-blind, placebo-controlled study. Am J Geriatr Psychiatry 11: 169-177, 2003
38. Vander Borght T, Minoshima S, Giordani B, Foster NL, Frey KA, Berent S, Albin RL, Koeppe RA, Kuhl DE: Cerebral metabolic differences in Parkinson's and Alzheimer's diseases matched for dementia severity. J Nucl Med 38: 797-802, 1997
39. Venneri A: Imaging treatment effects in Alzheimer's disease. Magn Reson Imaging 25:
953-968, 2007
40. Whitehouse PJ, Hedreen JC, White CL, 3rd, Price DL: Basal forebrain neurons in the dementia of Parkinson disease. Ann Neurol 13: 243-248, 1983
30 - ABSTRACT -